Abbott (NYSE:ABT) announced today that it received CE mark approval for its dual glucose-ketone sensing technology for people ...

The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.

Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual ...

Abbot has issued a medical device correction for some of its glucose sensor products after identifying a manufacturing issue that can lead to falsely low glucose readings. The correction affects about ...

Prospects for a less complicated, healthier future for Type 1 diabetics were heavily discussed at a major diabetes conference in Chicago over the weekend, including automated insulin delivery options ...

Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's issuing a voluntary medical device correction for some of its FreeStyle ...

Diabetes remains one of the nation’s most prevalent and dangerous chronic conditions, affecting nearly 15% of U.S. adults and causing more than 100,000 deaths each year. As a response, the landscape ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Abbott's world's leading1 and affordable2 integrated continuous glucose monitoring (iCGM) sensors are cleared for connectivity with automated insulin delivery (AID) systems in the U.S. Sensors also ...

Abbott Laboratories has taken a big step in diabetes management by integrating its glucose sensor with a Tandem insulin pump, creating a hybrid closed-loop insulin delivery system. The two companies ...

Abbott’s first dual-analyte sensor comes as competitors are working to develop their own versions of the technology.